Medical Condition News

RSS

Shire settles pending ADDERALL XR litigation with Sandoz

Shire plc, the global specialty biopharmaceutical company, announces that it has settled all pending litigation with Sandoz, Inc. ("Sandoz") in connection with Sandoz's Abbreviated New Drug Application ("ANDA") and its attempt to market generic versions of Shire's ADDERALL XR(R) (mixed amphetamine salts) for the treatment of Attention Deficit Hyperactivity Disorder.

14 Oct 2009

Invacare Corporation's initiative to raise awareness of Chronic Obstructive Pulmonary Disease

Invacare Corporation is sponsoring a bicycle expedition to raise awareness of Chronic Obstructive Pulmonary Disease (COPD) and inspire oxygen users to live active lives. The cyclist, Mark Junge, will be using the Invacare® XPO2™ Portable Oxygen Concentrator on his 816-mile trip. He will begin in New York City’s Times Square on October 15, 2009, and complete the trek in Charleston, South Carolina, on November 2, 2009.

14 Oct 2009

Researchers to investigate an existing drug for speedy recovery of stroke patients

New research will determine whether an inexpensive drug called L-dopa, widely used in the treatment of Parkinson's disease, could also help thousands of stroke patients regain mobility and independence.

14 Oct 2009

Bicycle-related injuries on the rise

Record-high gasoline prices, the slowdown in the economy, and increasing environmental sensitivity are leading more people to bike to work or for play. But an adequate infrastructure may not be in place to protect cyclists from serious injury according to surgeons who presented a new study on the issue during a scientific paper session at the 2009 Clinical Congress of the American College of Surgeons.

14 Oct 2009

Parkinson's patients with higher urate levels in their blood and CSF had slower functional decline

Individuals with Parkinson's disease who have higher levels of a metabolite called urate in their blood and in cerebrospinal fluid (CSF) have a slower rate of disease progression, according to a study funded by the National Institutes of Health.

14 Oct 2009

Gene variations increase the risk of sudden cardiac death

A multi-national research team has discovered that two genetic factors converge to increase the risk of sudden cardiac death.

14 Oct 2009

Positive results from Metabolex' Phase 1 MBX-2982 clinical trial for treating type 2 diabetes

Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from two multiple ascending dose Phase 1 clinical trials of MBX-2982.

14 Oct 2009

Epeius Biotechnologies announces clinical study results of tumor-targeted genetic medicine

Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world's first and, so far only, tumor-targeted genetic medicine to be validated in the clinic.

14 Oct 2009

Bladder cancer patients benefit from anticancer drug that is used to treat lung and colon malignancies: Study

An anticancer drug that is commonly used to treat lung and colon malignancies is having a benefit and potentially prolonging survival in patients with invasive bladder cancer, researchers reported at the 2009 Clinical Congress of the American College of Surgeons.

14 Oct 2009

Case Western Reserve University researchers step up to National Institutes of Health challenge

Futuristic plans to grow replacement organs, bones or muscles for soldiers maimed on the battlefield or patients suffering from debilitating disease or injury won't be anything but science fiction unless new blood vessels can grow into that tissue

14 Oct 2009

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

AVANIR Pharmaceuticals, Inc. today announced detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS).

14 Oct 2009

Timely and individualized publicly funded therapy denied to children with autism

With October being Autism Awareness Month in Canada, Ontarians should be aware of the increasingly large gaps in services for children with autism in this province.

14 Oct 2009

NIH awards Gladstone Institute consortium $3.7M for Huntington's disease research

The National Institutes of Health (NIH) has awarded a "Grand Opportunity" grant of $3.7 million to a consortium formed with the Gladstone Institute of Neurological Disease (GIND) and the Taube-Koret Center for Huntington's Disease Research to use stem cell technology to better understand Huntington's disease (HD) and to develop potential therapies.

14 Oct 2009

Bioluminescence imaging distinguishes tumor growth in vivo; leads to early treatment of eye cancer

At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.

14 Oct 2009

Positive results from Alkermes' ALKS 33 clinical trials announced

Alkermes, Inc. today announced positive topline data from two clinical trials of ALKS 33, an investigational oral opioid modulator for the treatment of addiction and other central nervous system disorders. Data from the studies, ALK33-003 and ALK33-004, showed that ALKS 33 was generally well tolerated and successfully blocked the effects of an opioid, with a duration of action that supports once daily dosing.

13 Oct 2009

Meda Pharmaceuticals introduces Onsolis for treating breakthrough cancer pain

Meda Pharmaceuticals Inc. today announced the launch of Onsolis(TM)(fentanyl buccal soluble film) in the U.S. for the management of breakthrough pain (BTP) in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

13 Oct 2009

PhysioNetics receives grant to continue development of 'gripper' for upper-extremity prostheses

A $750,000 Phase II grant from the National Institutes of Health will allow PhysioNetics, LLC to continue its development work on an innovative new “gripper” for upper-extremity prostheses.

13 Oct 2009

Interleukin Genetics to present new genetic findings on obesity and osteoporosis

Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today it will present new genetic findings in the fields of obesity and osteoporosis at medical meetings later this month.

13 Oct 2009

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Provectus Pharmaceuticals, Inc., a development stage oncology and dermatology biopharmaceutical company, has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. This milestone marks the third Phase 2 clinical trial for which Provectus has completed patient accrual since May 2009.

13 Oct 2009

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

Compugen Ltd. announced today that they have signed a collaboration agreement with Bayer Schering Pharma AG, Germany covering the further evaluation of a Compugen discovered tumor target and its splice variants.

13 Oct 2009

Medical Condition News

Shire settles pending ADDERALL XR litigation with Sandoz

Invacare Corporation's initiative to raise awareness of Chronic Obstructive Pulmonary Disease

Researchers to investigate an existing drug for speedy recovery of stroke patients

Bicycle-related injuries on the rise

Parkinson's patients with higher urate levels in their blood and CSF had slower functional decline

Gene variations increase the risk of sudden cardiac death

Positive results from Metabolex' Phase 1 MBX-2982 clinical trial for treating type 2 diabetes

Epeius Biotechnologies announces clinical study results of tumor-targeted genetic medicine

Bladder cancer patients benefit from anticancer drug that is used to treat lung and colon malignancies: Study

Case Western Reserve University researchers step up to National Institutes of Health challenge

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

Timely and individualized publicly funded therapy denied to children with autism

NIH awards Gladstone Institute consortium $3.7M for Huntington's disease research

Bioluminescence imaging distinguishes tumor growth in vivo; leads to early treatment of eye cancer

Positive results from Alkermes' ALKS 33 clinical trials announced

Meda Pharmaceuticals introduces Onsolis for treating breakthrough cancer pain

PhysioNetics receives grant to continue development of 'gripper' for upper-extremity prostheses

Interleukin Genetics to present new genetic findings on obesity and osteoporosis

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Latest News